E. Verspyck et al., Leuprorelin depot 3.75 mg versus lynestrenol in the preoperative treatmentof symptomatic uterine myomas: a multicentre randomised trial, EUR J OB GY, 89(1), 2000, pp. 7-13
Citations number
23
Categorie Soggetti
Reproductive Medicine
Journal title
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY
Objectives: To compare the effect of the gonadotrophin-releasing hormone ag
onist leuprorelin and progestin lynestrenol, given prior to surgical treatm
ent of symptomatic uterine myomas, on the pre-operative symptoms, tolerance
, and operative blood loss. Study design: Fifty-six women were randomly sel
ected to receive, during 16 weeks, either monthly subcutaneous injections o
f leuprorelin 3.75 mg sustained release (n=33) or lynestrenol 5 mg two tabs
per day (5th to the 25th menstrual cycle) (n=23). Results: Intent-to-treat
analysis of the main efficacy criterion, namely ultrasonographic reduction
of myoma(s) diameter, showed a significant difference in favour of leupror
elin (P=0.02) with a mean decrease of 26.5+/-4.5% (n=29) as opposed to 7.3/-5% in the lynestrenol group (n=17). Clinical improvement was satisfactory
in both groups. Hematocrit decrease between the preoperative value and the
value measured 48 h postoperatively was significantly lower in the leupror
elin group than in the lynestrenol one (P=0.02) (for hemoglobin: P=0.07). C
onclusion: Leuprorelin was more effective than lynestrenol because of its m
ore intense antigonadotropic activity. The tolerance was good, reflecting e
ach drug mechanism of action. (C) 2000 Elsevier Science Ireland Ltd. All ri
ghts reserved.